Quick Evidence Summary
| Evidence type | Current status |
|---|---|
| Human clinical trials | None published |
| Foundational animal study | 2018 diet-induced obese mouse study |
| Supporting cell-culture data | In vitro adipocyte data (increased NAD+/SAM, suppressed lipogenesis) |
| Compound classification | Synthetic small molecule, not a peptide |
| Regulatory status | Not FDA-approved; sold as a research chemical |
What 5-Amino-1MQ Is
5-Amino-1MQ is a synthetic small-molecule inhibitor of nicotinamide N-methyltransferase (NNMT), an enzyme expressed at elevated levels in white adipose tissue. By blocking NNMT, it's studied for its ability to preserve intracellular NAD+ and reduce fat cell growth without stimulant-driven mechanisms. Worth noting up front: 5-Amino-1MQ is not a peptide, it's a methylquinolinium small molecule, though it's commonly marketed and sold alongside peptides in the research chemical space, which is why it shows up in peptide-focused catalogs and guides.
Why There's No Human Trial Data Yet
No completed human clinical trials of 5-Amino-1MQ have been published. The evidence base is preclinical. The compound was developed and characterized as a selective, membrane-permeable NNMT inhibitor and tested in diet-induced obese mice, where it reduced body weight and white adipose mass, lowered plasma cholesterol, and decreased adipocyte size without changing food intake, alongside supporting in vitro adipocyte data showing increased NAD+ and SAM and suppressed lipogenesis.
Why this matters: the animal data is genuinely promising and mechanistically coherent, but it's still a single foundational mouse study plus cell-culture work, not a replicated human trial program. Claims about human fat loss or metabolic-rate effects remain extrapolations from animal and cell-culture data rather than confirmed human outcomes.
Why the Mouse Dose Doesn't Translate Directly
The foundational mouse study used 20mg/kg administered subcutaneously three times daily, a dosing route and frequency quite different from how the compound is used in research-community practice. The 50-150mg/day oral range circulating in research-community protocols is a convention drawn from vendor and community sources rather than a published, peer-reviewed human dosing trial, and should be treated as a loosely established starting reference, not a validated figure.
Regulatory Status
5-Amino-1MQ has not been evaluated or approved by the FDA for any human indication, and it is not currently listed on the FDA's 503A or 503B bulk drug substance lists for compounding pharmacies. Products sold as 5-Amino-1MQ, including the one carried in the BioStackIQ shop, are marketed and sold as research chemicals for laboratory and research use only, not for human consumption. This is a legal distinction, not a safety endorsement: research-use framing does not indicate that a product has been evaluated by any regulator for human safety or efficacy.
Bloodwork to Track
Given the proposed mechanism, a lipid panel and liver function panel are reasonable things to track given the compound's studied effects on cholesterol and fat metabolism. See the peptide bloodwork guide for what a general baseline panel typically includes.
Related Reading
For research dosing conventions and the full regulatory breakdown, see the 5-Amino-1MQ reference page. BioStackIQ's Rate My Stack and Build Protocol can help you think through where a compound like this fits into a broader stack, with this evidence picture in mind.